-
Magic Mushrooms For Anorexia? Clinical Study Receives FDA Approval For Phase 2 Trial
Sunday, September 25, 2022 - 12:16pm | 214Read More...Origin Therapeutics Holdings Inc. (CSE: ORIG), a psychedelics industry-focused investment issuer, announced that one of its portfolio companies, Xpira Pharmaceuticals, has obtained approval from the FDA for its first Investigational New Drug (IND) application for a...
-
Origin Therapeutics Attaches Clairvoyant To Its Portfolio, Fueling Fast Market Strategy For Psilocybin Therapy
Thursday, July 7, 2022 - 4:10pm | 363Read More...Psychedelics investment issuer Origin Therapeutics Holdings Inc. has added Canadian biotech psychedelics developer Clairvoyant Therapeutics to its portfolio. The company’s clinical strategy is designed to enable psilocybin therapy in the European Union, UK and Canada for patients...
-
New Psychedelic Investment Opportunity: Look For "ORIG" (Origin Therapeutics) On The CSE Starting June 6
Thursday, June 2, 2022 - 12:17pm | 349Read More...The Canadian Securities Exchange (CSE) is about to provide another option for those interested in the nascent psychedelic industry. Origin Therapeutics Holdings, a psychedelics industry-focused investment issuer will debut on the CSE on June 6 under the symbol "ORIG....
